PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis

PKCλ/ι抑制激活ULK2介导的干扰素反应,从而抑制肿瘤发生

阅读:6
作者:Juan F Linares ,Xiao Zhang ,Anxo Martinez-Ordoñez ,Angeles Duran ,Hiroto Kinoshita ,Hiroaki Kasashima ,Naoko Nakanishi ,Yuki Nakanishi ,Ryan Carelli ,Luca Cappelli ,Esperanza Arias ,Masakazu Yashiro ,Masaichi Ohira ,Sanjay Patel ,Giorgio Inghirami ,Massimo Loda ,Ana Maria Cuervo ,Maria T Diaz-Meco ,Jorge Moscat

Abstract

The interferon (IFN) pathway is critical for cytotoxic T cell activation, which is central to tumor immunosurveillance and successful immunotherapy. We demonstrate here that PKCλ/ι inactivation results in the hyper-stimulation of the IFN cascade and the enhanced recruitment of CD8+ T cells that impaired the growth of intestinal tumors. PKCλ/ι directly phosphorylates and represses the activity of ULK2, promoting its degradation through an endosomal microautophagy-driven ubiquitin-dependent mechanism. Loss of PKCλ/ι results in increased levels of enzymatically active ULK2, which, by direct phosphorylation, activates TBK1 to foster the activation of the STING-mediated IFN response. PKCλ/ι inactivation also triggers autophagy, which prevents STING degradation by chaperone-mediated autophagy. Thus, PKCλ/ι is a hub regulating the IFN pathway and three autophagic mechanisms that serve to maintain its homeostatic control. Importantly, single-cell multiplex imaging and bioinformatics analysis demonstrated that low PKCλ/ι levels correlate with enhanced IFN signaling and good prognosis in colorectal cancer patients. Keywords: STING; ULK1/2; atypical PKC; autophagy; chaperone-mediated autophagy; colorectal cancer; immunosuppression; immunosurveillance; immunotherapy; interferon.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。